Clinical trial · Interventional
EUS-B-FNA vs EUS-FNA for Left Adrenal Gland Analysis in Lung Cancer Patients
EUS-B-FNA vs EUS-FNA for Left Adrenal Gland Analysis in Lung Cancer
NCT02538380CI-TRIAL-00019008unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare EUS-B-FNA (using the EBUS scope)with EUS-FNA for left adrenal gland analysis in lung cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Suspected Left Adrenal Gland Metastasis in Lung Cancer | Lung Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS-B-FNA followed by EUS-FNA for LAG analysis | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EUS-B-FNA for LAG analysis
- description
- All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
- interventionNames
- Procedure: EUS-B-FNA followed by EUS-FNA for LAG analysis
Primary outcomes (1)
- measure
- The proportion of patients with a successful EUS-B-FNA procedure for LAG analysis.
- timeFrame
- within 3 weeks after inclusion
- description
- Successful is defined as: LAG is visible, sampling is possible and adequate material for cytopathological evaluation is obtained.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * (Suspected) Lung Cancer * For malignancy suspected LAG on imaging (enlarged based on CT and/or FDG avid based on FDG-PET); * Indication for endosonographic mediastinal staging by EBUS; * Indication for LAG sampling; Exclusion Criteria: * Contraindication for EUS; * Pregnancy;
References
Publications (0)
Data not yet available
No reference posted for this study.